N'-ETHOXY-N-(3,4,5-TRIETHOXYPHENYL)FORMIMIDAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	AVGWNVRHNNCIDI-UHFFFAOYSA-N
Smiles	CCO\N=C\Nc1cc(OCC)c(OCC)c(OCC)c1
InChI	InChI=1S/C15H24N2O4/c1-5-18-13-9-12(16-11-17-21-8-4)10-14(19-6-2)15(13)20-7-3/h9-11H,5-8H2,1-4H3,(H,16,17)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H24N2O4
Molecular Weight	296.36
AlogP	2.32
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	10.0
Polar Surface Area	61.31
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	21.0

Assay Description	Organism	Bioactivity
Phytotoxicity against Phaseolus vulgaris (kidney bean) assessed as necrosis of leaf at 100 ppm after 7 days in greenhouse conditions	Phaseolus vulgaris	None
Fungicidal activity against benzimidazole-resistant Botryotinia fuckeliana infected kidney bean leaf at 100 ppm after 7 days in greenhouse conditions by detached leaf test	Botryotinia fuckeliana	25.0 %
Fungicidal activity against benzimidazole-resistant Botryotinia fuckeliana at 6.2 ppm after 48 hr by poisoned food technique	Botryotinia fuckeliana	25.0 %
Fungicidal activity against benzimidazole-resistant Botryotinia fuckeliana at 25 ppm after 48 hr by poisoned food technique	Botryotinia fuckeliana	26.0 %
Fungicidal activity against benzimidazole-resistant Botryotinia fuckeliana at 200 ppm after 48 hr by poisoned food technique	Botryotinia fuckeliana	100.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2286291
PubChem	13579542

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).